Introduction Since IgA nephropathy (IgAN) was first described in 1968, it has been recognized as the most common primary glomerulonephritis in the world, affecting mainly adolescents and young adults. Clinically, IgAN manifests either as macroscopic hematuria coinciding with mucosal infections or persistent hematuria with or without proteinuria. Nephrotic syndrome and rapidly progressive glomerulonephritis with crescent formation are uncommon. End-stage renal disease develops in 20% to 30% of the patients within 20 years. Clinical markers of unfavorable outcome are hypertension, degree of proteinuria, persistence of erythocyturia, and renal impairment. 1, 2 IgAN is an autoimmune disorder, characterized by the mesangial deposition of IgA1-IgG complexes. IgA1 galactosylation defect is responsible for the immunogenicity of IgA1. Galactose deficient O-glycans are recognized by IgG and form complexes deposited in the mesangium activating an inflammatory cascade. 3 Currently, the diagnosis of IgAN is based on the confirmation of IgA deposits in kidney biopsy, which is an invasive procedure. The course of the disease, including the development of endstage renal disease, is heterogenous; therefore, noninvasive diagnostic and prognostic biomarkers are needed. Serum levels of galactose-deficient IgA1 and glycan-specific IgG are potential diagnostic and prognostic biomarkers of IgA nephropathy. 4 Recently, a quantitative assessment of IgA galactosylation status has been developed. It has been reported that IgA O-glycosylation status improves with immunosuppressive therapy; therefore, it may serve as a marker of therapeutic response.
5 Some potential biomarkers were correlated with biopsy findings. Urinary mannosebinding lectin correlated with clinical and histopathological parameters conventionally predicting progression of IgAN.
6 Serum soluble interleukin 2 receptor alpha chain was shown to predict progression of IgAN and correlated with fibrotic lesions in biopsies.
7 Serum vascular cell adhesion correlations between biomarkers and qualitative data-either by the t test or Mann-Whitney test. For all tests, A P value of less than 0.05 was considered significant. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee. A written informed consent was obtained from all subjects included in the study.
Results
Patients with IgAN are characterized by increased plasma and urinary concentrations of IL-17A (Table) . Plasma and urinary IL-17A concentrations in all other chronic nephropathies were not different from those in the control group. Plasma IL-17A was increased in patients with MCD with active urinary sediment (P = 0.037).
In patients with IgAN, urinary IL-17A correlated negatively with glomerular filtration rate (GFR; r = -0.4; P = 0.03) and hemoglobin (r = -0.5; P = 0.016). Neither plasma nor urinary IL-17A concentrations correlated with daily proteinuria in any of the chronic nephropathies.
Urinary IL-17A concentrations were higher in patients with membranous nephropathy and FSGS with diabetes (P = 0.007 and P = 0.047, respectively) and with hypertension (P = 0.011 and P = 0.012, respectively).
Steroid (prednisone dose), ACEI, or cyclosporine therapy was not correlated either with plasma or urinary IL-17A concentrations. In IgAN patients, plasma IL-17A concentrations were higher in patients treated with statins (P = 0.04).
IgAN patients were divided into 2 groups depending on renal biopsy findings: patients with an FSGS pattern and those with a proliferative proteinuria was calculated using the protein--to-creatinine ratio from a single morning urine sample.
IgAN patients were treated with oral steroids, cyclosporine, or a combination of both. A mean serum cyclosporine concentration was 9.03 ng/ml. A mean oral daily prednisone dose was 15.12 mg. Fifteen patients (65.2%) took also angiotensin-converting enzyme inhibitors (ACEIs). Seven patients received only steroids (5 with an FSGS lesion pattern, 2 with a proliferative pattern). Only 1 patient (with an FSGS pattern) received monotheraphy with cyclosporine. In addition, only 1 patient (with a proliferative pattern) was treated with adrenocorticotropic hormone with cyclosporine. Three patients were treated with the combination of steroids and cyclosporine (1 with an FSGS pattern, 2 with a proliferative pattern). Of the remaining 11 patients without immunosuppression, 4 did not receive any drugs (2 with an FSGS pattern and 2 with a proliferative pattern) and 7 received a monotherapy with ACEIs (4 with a proliferative pattern and 3 with an FSGS pattern).
Normal distribution of the data was assessed by the D'Agostino-Pearson test. A correlation between biomarker concentrations and the type of nephropathy was tested by means of the analysis of variance with a post hoc analysis using the Student-Newman-Keuls method for data with normal distribution or the Kruskall-Wallis test with a post hoc analysis according to the Conover method for data without normal distribution. Correlations between biomarkers and quantitative laboratory data were assessed using the Spearman correlation coefficient, while 
